Whitepapers
Innovative access agreements for ATMPs in Europe
Why embrace them? By Chloe Sheppard, Erfan Akbraian, Andrea Bernardini & Richard Wang Advanced Therapy Medicinal Products (ATMPs) have significant potential to transform the lives
BeNeLuxA and FiNoSe joint initiative
Are they as beneficial to manufacturers as they seem? By Joana Fernandes & Ashkay Kumar What are the research aims? Products that are being reviewed
Expanded Access Programs (EAPs) in Europe
Are they right for your therapy? By Maximus Rex & Nicola Allen Drug development is a long and costly process. It is not uncommon for
Tools for 2020 success: 10 trends you should know in orphan drug, cell and gene therapy
2019 set the tone for innovative therapies in the cell and gene therapy space along with huge interest from Big Biotech. With an expected double
Treatment without borders for Cell & Gene Therapies: Are we there yet?
“Cross border access”, “hub models”, “highly centralised access models” are only a few buzz words to refer to the pathway that enables European Union (EU)
Orphan Drugs in Colombia: Practical Limitations to Access
By Ciaran Cassidy, Analyst Email: [email protected] Colombia, like much of Latin America, is receiving attention from the pharmaceutical industry as an emerging market (1). Through
Scaling the healthcare wall: is Mexico an attractive market for high cost drug makers?
By Jack Rawson, Analyst Email: [email protected] At first glance Mexico presents a significant opportunity for drug manufacturers, with a large population of over 126 million,
Future-proofing 2019 plans: P4A’s 6 Orphan Drug, Cell & Gene Therapy trends to watch out for
2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will
Rare Diseases: A New Purpose
How drug repurposing could help drive orphan drug access if pharma can accept the risks By Nader Murad, Senior Analyst Email: [email protected] The US National
